Observational studyJournal of endocrinological investigation2018
How to improve effectiveness of pegvisomant treatment in acromegalic patients.
Observational study in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies.Endocrine · 2019Pooled it
- Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly.Endocrinology · 2026Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management.Journal of endocrinological investigation · 2024Article
- Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis.Endocrine connections · 2024Article
- Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas.Frontiers in endocrinology · 2022Article
- More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.European journal of endocrinology · 2021Article
- A Pituitary Society update to acromegaly management guidelines.Pituitary · 2021Review
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.Frontiers in endocrinology · 2020Review
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center.Endocrine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study. The aim was to detect characteristics which improve long-term PEGV effectiveness.
methods87 acromegalic patients treated with PEGV have been enrolled in seven referral Italian centres. PEGV was administered for up to 4 years, at doses up titrated until IGF-1 normalization or to ≥ 30 mg/day. The rate of patients who reached IGF-1 normalization at last visit has been calculated.
resultsIGF-1 was normalized in 75.9% of patients after 1 year and in 89.6% at last visit. Disease control was associated with lower baseline GH, IGF-1 and IGF-1 xULN and was more frequent when baseline IGF-1 was < 2.7 × ULN (p < 0.02). PEGV dose was dependent on baseline IGF-1 > 2.7 × ULN (p < 0.05) and doses > 1.0 mg/BMI/day were administered more frequently when baseline IGF-1 was > 2.0 × ULN (p = 0.03). PEGV resistance was associated with higher BMI (p = 0.006) and was more frequent when BMI was > 30 kg/m
conclusionsPEGV effectiveness improves when up titration is appropriate. Higher PEGV doses at start and a more rapid up-titration are necessary in patients with obesity and/or IGF-1 > 2.7 × ULN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.